From: Use of immunohistochemical markers can refine prognosis in triple negative breast cancer
Univariate | Full Multivariate | Parsimonious | ||||||
---|---|---|---|---|---|---|---|---|
Model | Variable | RR (95% CI) | P | RR (95% CI) | P | RR (95% CI) | P | |
Model 1 | CK5/6+ and/or EGFR+ | No | 1. | 1. | 1. | |||
Yes | 2.00 [1.33; 3.02] | 0.0009 | 1.95 [1.18; 3.21] | 0.009 | 1.92 [1.27; 2.89] | 0.002 | ||
TNP | No | 1. | 1. | |||||
Yes | 1.71 [1.05; 2.78] | 0.03 | 0.96 [0.51; 1.79] | 0.89 | not present | |||
Model 2 | PR | No | 1. | 1. | 1. | |||
Yes | 0.59 [0.40; 0.85] | 0.005 | 0.64 [0.42; 0.98] | 0.04 | 0.62 [0.42; 0.92] | 0.02 | ||
CBP | No | 1. | 1. | |||||
Yes | 1.72 [1.06; 2.80] | 0.03 | 1.18 [0.64; 2.17] | 0.60 | not present | |||
Model 3 | ER- HER2- | No | 1. | 1. | 1. | |||
Yes | 1.96 [1.30; 2.97] | 0.002 | 1.41 [0.80; 2.49] | 0.24 | 1.64 [0.99; 2.70] | 0.05 | ||
PR | No | 1. | 1. | |||||
Yes | 0.59 [0.40; 0.85] | 0.005 | 0.77 [0.49; 1.20] | 0.24 | not present | |||
CK5/6+ and/or EGFR+ | No | 1. | 1. | 1. | ||||
Yes | 2.00 [1.33; 3.02] | 0.0009 | 1.54 [0.92; 2.58] | 0.10 | 1.69 [1.04; 2.74] | 0.03 |